anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention provides a transgenic mouse which exhibits a circling phenotype as a result of insertional mutagenesis. The insertional mutant was caused by introducing genetic material into the genome of the mouse, or an ancestor thereof, at an embryonic stage. The genetic material appears to alter or disrupt an endogenous genetic locus affecting motor function, resulting in the mutation. More particularly, transgenic mouse lines were made by microinjection of about 24 kb XhoI genomic DNA fragment containing the mouse Ren-2 d  renin gene into BCF 1 , fertilized eggs. One transgenic mouse line, designated TgX15 (also known as chakragati mice), bred to homozygosity was found to exhibit a circling phenotype. The transgenic mouse line TgX15 may be an important resource for investigating the molecular genetic mechanisms that determine specific aspects of brain function and behavior. Also, these mice may be useful to evaluate new and potentially more effective agents for the therapeutic treatment of disorders involving dopaminergic dysfunction such as Parkinsonism and schizophrenia.
Patients receive docetaxel IV over 30 minutes on days 1, 8, and 15 and cetuximab IV over 1-2 hours on days 1, 8, 15, and 22. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients with responding or stable disease after 4 courses receive cetuximab alone as above in the absence of disease progression or unacceptable toxicity.
The initial dose of bosentan was 2 mg/kg b.i.d. for 4 weeks. After 4 weeks, the initial dose was up-titrated to the maintenance dose of 4 mg/kg b.i.d. up to the end of the study treatment at Week 12. If the maintenance dose was not well tolerated, the dose could be down-titrated to the initial dose.
Multiple system atrophy (MSA) is a neurodegenerative disorder characterized by various combinations of autonomic failure, parkinsonism, and cerebellar ataxia. To elucidate variants associated with MSA, we have been conducting short-read-based whole-genome sequence analysis. In the process of the association studies, we initially focused on GBA1, a previously proposed susceptibility gene for MSA, to evaluate whether GBA1 variants can be efficiently identified despite its extraordinarily high homology with its pseudogene, GBA1LP. To accomplish this, we conducted a short-read whole-genome sequence analysis with alignment to GRCh38 as well as Sanger sequence analysis and compared the results. We identified five variants with inconsistencies between the two pipelines, of which three variants (p.L483P, p.A495P-p.V499V, p.L483_M489delinsW) were the results of misalignment due to minor alleles in GBA1P1 registered in GRCh38. The miscalling events in these variants were resolved by alignment to GRCh37 as the reference genome, where the major alleles are registered. In addition, a structural variant was not properly identified either by short-read or by Sanger sequence analyses. Having accomplished correct variant calling, we identified three variants pathogenic for Gaucher disease (p.S310G, p.L483P, and p.L483_M489delinsW). Of these variants, the allele frequency of p.L483P (0.003) in the MSA cases was higher than that (0.0011) in controls. The meta-analysis incorporating a previous report demonstrated a significant association of p.L483P with MSA with an odds ratio of 2.85 (95% CI; 1.05 - 7.76, p = 0.0400).
Two pairs of twins discordant for Down syndrome and 1 children with mosaic Down syndrome will be recruited. Blood, skin and feces samples will be specifically collected for the purpose of the study.
Whenever possible, serum tobramycin concentrations should be monitored during therapy. 

Following a loading dose of 1 mg/kg, subsequent dosage in these patients must be adjusted, either with reduced doses administered at 8-hour intervals or with normal doses given at prolonged intervals. Both of these methods are suggested as guides to be used when serum levels of tobramycin cannot be measured directly. They are based on either the creatinine clearance or the serum creatinine of the patient, because these values correlate with the half-life of tobramycin. The dosage schedules derived from either method should be used in conjunction with careful clinical and laboratory observations of the patient and should be modified as necessary. Neither method should be used when dialysis is being performed. 

Reduced Dosage at 8-hour Intervals — When the creatinine clearance rate is 70 mL or less per minute or when the serum creatinine value is known, the amount of the reduced dose can be determined by multiplying the normal dose from Table 3 by the percent of normal dose from the accompanying nomogram. 

An alternate rough guide for determining reduced dosage at 8-hour intervals (for patients whose steady-state serum creatinine values are known) is to divide the normally recommended dose by the patient's serum creatinine. 

* Scales have been adjusted to facilitate dosage calculations. 

Normal Dosage at Prolonged Intervals — If the creatinine clearance rate is not available and the patient's condition is stable, a dosage frequency in hours for the dosage given in Table 3 can be determined by multiplying the patient's serum creatinine by 6.
BACKGROUND: Immunoglobulin derived AL amyloidosis and transthyretin derived ATTR amyloidosis are the most common forms of cardiac amyloidosis. Both may present with cardiac arrhythmias, heart failure, and extracardiac symptoms. Disease outcome is often fatal. Recently, it was proposed that amyloid may cause cardiac inflammation. Here we tested the hypothesis that immune cell infiltration in cardiac tissue correlates with clinicopathological patient characteristics.
PATIENTS AND METHODS: Myocardial biopsies from 157 patients with cardiac amyloidosis (46.5% AL, 53.3% ATTR) were immunohistochemically assessed for the presence and amount of T lymphocytes (CD3), macrophages (CD68) and neutrophils (MPO). Amyloid load, cardiomyocyte diameter, apoptosis (Caspase 3), necrosis (complement 9), and various clinical parameters were assessed and correlated with immune cell density.
RESULTS: Myocardial tissue was infiltrated with T lymphocytes (CD3), macrophages (CD68) and neutrophils (MPO) with variable amounts. Significant correlations were found between the number of macrophages and NYHA class. No correlations were found between the presence and amount of T lymphocytes, neutrophils and clinicopathological patient characteristics.
CONCLUSION: The significant correlation between cardiac macrophage density and heart failure points towards a significant role of macrophages in disease pathology.
BACKGROUND: HIV testing remains an important tool in identifying people living with HIV/AIDS (PLWHA). An early diagnosis of HIV can lead to a prolonged life expectancy if treatment is initiated promptly. Indicator conditions can be the first sign of an HIV infection and should therefore be recognised and consequently a HIV test should be carried out. Testing should occur in all individuals as sexuality can be experienced by everyone, and stigma can lead to the exclusion of vulnerable groups, leading to a gap in diagnosis and treatment [1, 2].
CASE PRESENTATION: A 63-year-old man, who identifies as bisexual and has had an intellectual disability since birth, presented at our health care centre for HIV testing. A decade ago, the patient was diagnosed with Stage III Diffuse Large B-cell Non-Hodgkin Lymphoma, an AIDS defining cancer. The patient presented at a Haematology and Oncology department 3 months prior, due to a weight loss of 10 kg over the past 5 months. Oral thrush, an HIV-indicator condition, had been diagnosed by the otolaryngologists shortly before. During this medical evaluation, pancytopenia was identified. Despite the presence of indicator conditions, the patient was never tested for HIV in the past. Staff members from the care facility for intellectually disabled suggested conducting a HIV test in our clinic through the public health department, where HIV positivity was revealed. The AIDS-defining diagnosis, along with a CD4 + cell count of 41/µl, suggests a prolonged period of HIV positivity.
CONCLUSION: Due to the presence of existing indicator conditions, an earlier HIV diagnosis was possible. We contend that most of the recent illnesses could have been prevented if earlier testing had been carried out. Therefore, patients presenting with AIDS indicator conditions, including those with mental disabilities, should be given the opportunity to be tested for HIV. HIV/AIDS trainings should be made available to health care professionals as well as to personnel interacting with vulnerable groups.
Perform a 250cc vascular filling over 10 minutes and then perform a cardiac ultrasound. Repeat the vascular filling followed by the ultrasound as long as the patient is responsive.
Based on findings from animal studies and its mechanism of action, Temozolomide can cause fetal harm when administered to a pregnant woman. Adverse developmental outcomes have been reported in both pregnant patients and pregnant partners of male patients. Oral administration of Temozolomide to rats and rabbits during the period of organogenesis resulted in embryolethality and polymalformations at doses less than the maximum human dose based on body surface area.

Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with Temozolomide and for at least 6 months after the final dose. Because of potential risk of genotoxic effects on sperm, advise male patients with female partners of reproductive potential to use condoms during treatment with Temozolomide and for 3 months after the final dose. Advise male patients not to donate semen during treatment with Temozolomide and for 3 months after the final dose [see Use in Specific Populations ( 8.1, 8.3)].
PROBLEM TO BE SOLVED: To provide a hair-dyeing agent having sufficient hair-dyeing ability and a hair-dying method. SOLUTION: The hair-dyeing agent contains the dried powder of the leaves of henna, an alkali agent and water. The dried powder of the leaves of henna is mixed to dye the hair based on the dyeing components contained in the leaves of henna. The content of the dried powder of the leaves of henna is preferably in a range of 1 to 50 wt.%, more preferably 5 to 35 wt.%. The alkali agent is mixed to increase the hair dyeing ability of the hair-dyeing components contained in the dried powder of the leaves of henna, and its content is preferably in a range of 1 to 30 wt.%, more preferably 2 to 20 wt.%. The water is mixed to dissolve the dyeing components contained in the dried powder of the leaves of henna, and is content is preferably in a range of 20 to 98 wt.%, more preferably 45 to 93 wt.%.  The hair dyeing is made as follows: after the first agent containing the dried powder of the leaves of henna, the alkali agent and the water is applied to the hair, the second agent containing an acid is applied to the hair.
BACKGROUND: While many transgender and gender diverse individuals rapidly achieve amenorrhea on testosterone, emerging data have identified that breakthrough bleeding can occur in up to one-third of individuals with long-term use. Breakthrough bleeding can worsen dysphoria and patients may seek management to reattain amenorrhea. Because of this, there is a need to assess efficacy of management approaches.
OBJECTIVE: The primary aim of the study was to evaluate methods used by patients and their providers to manage breakthrough bleeding which arises after 1 year of testosterone use. Secondary aims included describing the diagnostic approaches to breakthrough bleeding, and proposing an algorithm for classification and management of breakthrough bleeding in this patient population.
STUDY DESIGN: This was an institutional review board-approved single tertiary center, retrospective chart review of transgender and gender diverse individuals on testosterone gender affirming hormone therapy who experienced breakthrough bleeding after 1 year of use. Charts were reviewed to determine patient characteristics, testosterone use, and breakthrough bleeding management approaches.
RESULTS: Of the 96 individuals who had been on testosterone for 1 year and experienced breakthrough bleeding, 97% (n=93) engaged in at least 1 approach to management. The mean age at initiation of testosterone was 21.9 (standard deviation 5.4) and the median duration of time on testosterone was 54.5 months (interquartile range 33.5, 82). Only 16% (n=15) were using menstrual suppression at the time of their breakthrough bleeding episode. Breakthrough bleeding was successfully managed in 77 (79%), following between 1 and 4 attempted approaches. More than half of management attempts (63%) were successful on the first try. When management approaches were analyzed independently, the range of success associated with any particular approach was between 33% and 100%. Other than hysterectomy, which was fully successful at managing breakthrough bleeding, no approach was significantly better than no intervention. This was true both for individuals who did and did not bleed with missed testosterone doses. Regardless of what approach was used, after a failed attempt, the next attempt was successful in more than half of individuals. Of the 16 who underwent hysterectomy, 1 did so in part as a first line approach to manage breakthrough bleeding.
CONCLUSION: In this study, use of medical management methods was not found to be superior to observation alone in the management of breakthrough bleeding. In the absence of data supporting superiority of any method, we recommend tailoring method attempts to patients' goals.
Statins interfere with cholesterol synthesis and lower circulating cholesterol levels and, as such, might theoretically blunt adrenal or gonadal steroid hormone production. Results of clinical trials with pravastatin in males and post-menopausal females were inconsistent with regard to possible effects of the drug on basal steroid hormone levels. In a study of 21 males, the mean testosterone response to human chorionic gonadotropin was significantly reduced (p<0.004) after 16 weeks of treatment with 40 mg of pravastatin. However, the percentage of patients showing a ≥50% rise in plasma testosterone after human chorionic gonadotropin stimulation did not change significantly after therapy in these patients. The effects of statins on spermatogenesis and fertility have not been studied in adequate numbers of patients. The effects, if any, of pravastatin on the pituitary-gonadal axis in pre-menopausal females are unknown. Patients treated with pravastatin who display clinical evidence of endocrine dysfunction should be evaluated appropriately. Caution should also be exercised if a statin or other agent used to lower cholesterol levels is administered to patients also receiving other drugs (e.g., ketoconazole, spironolactone, cimetidine) that may diminish the levels or activity of steroid hormones. 

In a placebo-controlled study of 214 pediatric patients with HeFH, of which 106 were treated with pravastatin (20 mg in the children aged 8 to 13 years and 40 mg in the adolescents aged 14 to 18 years) for 2 years, there were no detectable differences seen in any of the endocrine parameters (ACTH, cortisol, DHEAS, FSH, LH, TSH, estradiol [girls] or testosterone [boys]) relative to placebo. There were no detectable differences seen in height and weight changes, testicular volume changes, or Tanner score relative to placebo.
Local heat will be applied using a Localized Current Field radio-frequency generating device manufactured by Thermo-Med Technologies, Inc. A wand with 2 electrodes is connected to the main housing by a thin wire. The electrodes are applied to the skin. We will use electrodes 6 mm long, separated by 4 mm. One single session at the site of the lesion(s) at 50°C for 30" applications will be used. Depending on the size of the lesion, more than one application may be administered.
PURPOSE:To achieve the remarkable remedying and preventive effect to bacteriosis caused by Gram-positive bacteria, especially resistant staphylococci, by the synergistic effect of the components, by mixing or combining a cephalosporin or penicillin-type antibiotic substance with a cephamycin-type antibiotic substance. CONSTITUTION:A cephalosporin-type antibiotic substance (e.g. cefazolin, cephaloridine, etc.) or a penicillin-type antibiotic substance (e.g. ampicillin, piperacillin, etc.) is mixed or combined with a cephamycin-type antibiotic substance (e.g. cefmetazole, cefoxitin, etc.) to obtain a drug for the remedy and prevention of bacteriosis by the synergistic effect. The ratio of the cephalosporin-type antibiotic substance, etc. to the cephamycin-type antibiotic substance is preferably 5:1- 1:5. The synergistic effect attained by the present invention is especially effective against the bacterial strain resistant to cephem-type or penicillin-type antibiotic substance.
The present disclosure relates to a network system. The system is formed by at least two negative pressure wound therapy (NPWT) devices. The first NPWT device includes a wireless radio, user interface, controller, and processing circuit. The wireless radio wirelessly communicates with the second NPWT device. The user interface displays operational status of therapy operation, receives a command of operational change from a user, and displays wireless radio connection strength between the first NPWT device and the NPWT device. The controller controls therapy operation of the first NPWT device based on input from the user interface. The processing circuit causes the wireless radio to communicate with the second NPWT device, determines wireless radio connection strength between the first NPWT device and the second NPWT device based on communication between the first NPWT device and the second NPWT device, and causes the user interface to display determined wireless radio connection strength.
Neutral stable aqueous solutions of complex metallic compounds of the alkali salts of <FORM:0376346/IV/1> in which R1 represents hydrogen or a hydroxy group, R2 stands for a sulphonic or carboxylic acid group, and R3 signifies hydrogen or a sulphonic acid group, are prepared by incorporating sulphites in small quantity with the solutions of the said complex compounds and then neutralizing.  The resulting solutions are suitable for injection.  Examples are given of the preparation of solutions of antimonyl pyrocatechol sodium mono- and di-sulphonates, antimonyl pyrogallol sodium disulphonate, manganese pyrocatechol sodium disulphonate, the sodium salt of antimonyl protocatechnic acid, the potassium salt of antimonyl pyrocatechol-o-carboxylic acid, and bismuth and arsenous pyrocatechol sodium disulphonates using sodium metabisulphite.  Other sulphites mentioned are potassium and ammonium metabisulphites, sodium, potassium and ammonium bisulphites or sulphites, and mixtures thereof.ALSO:Neutral stable aqueous solutions of complex metallic compounds of the alkali salts of <FORM:0376346/VI/1> in which R1 represents hydrogen or a hydroxy group, R2 stands for a sulphonic or carboxylic acid group, and R3 signifies hydrogen or a sulphonic acid group, are prepared by incorporating sulphites in small quantity with the solutions of the said complex compounds and then neutralizing. The resulting solutions are suitable for injection.  Examples are given of the preparation of solutions of antimonyl pyrocatechol sodium mono- and disulphonates, antimonyl pyrogallol sodium disulphonate, manganese pyrocatechol sodium disulphonate, the sodium salt of antimonyl protocatechuic acid, the potassium salt of antimonyl pyrocatechol-o-carboxylic acid, and bismuth and arsenous pyrocatechol sodium disulphonates using sodium metabisulphite. Other sulphites mentioned are potassium and ammonium metabisulphites, sodium, potassium, and ammonium bisulphites or sulphites, and mixtures thereof.
Sepsis cluster therapy + Shenhuang granules for 5 days. For the treatment of sepsis cluster, refer to the 2021 International Guidelines for Severe Sepsis and Septic Shock. Shenhuang Granules (Tianjin Hongri Pharmaceutical Co., LTD.) : 2 times a day, 1 pack each time, 100ml of warm water (temperature about 40°C) after dissolution, oral or nasal feeding (stomach tube or intestinal tube).
FIELD: medicine. ^ SUBSTANCE: invention concerns protein NMB1870 which represents common surface protein Neisseria meningitidis expressed with all Neisseria serogroups. Protein is subdivided into three separate families. The whey induced against antigen of a certain family, has bactericidal effect within this family, but is inactive concerning strains expressing antigens of one of other two families, i.e. there is a cross protection within family, but not between families. It is established, that NMB1870 can be subdivided into domains and that antigen domains can be recovered from NMB1870 of all three families and expressed as a polypeptide chain that is implemented by the method disclosed in the invention. Also it is discovered that NMB1870 expresses some epitopes in surface loops located between alpha spirals, and that epitope substitution of the loop of one family with that of the other family enables making chimeric NMB1870 of antigenicity characteristic for proteins of several families. In the invention there are disclosed chimeric proteins NMB1870 (versions) partially containing NMB1870 of various families. ^ EFFECT: proteins produced according to the invention can be used as a medical agent as a component of immunological compositions for immunization against diseases caused by Neisseria meningitidis without family specificity of protection. ^ 22 cl, 46 dwg
The invention relates to indazole derivatives, a preparation method and application thereof, belonging to the field of chemical medicine. The invention provides a compound shown as a formula I. The invention also provides a preparation method and application of the compound. Biological experiments show that the compounds have obvious inhibition effect on the activity of kinases such as FGFR and the like, can effectively inhibit the proliferation of a plurality of cancer cells such as breast cancer, lung cancer, gastric cancer and the like, and have broad-spectrum anticancer effect. In addition, the composition also shows an inhibiting effect on the proliferation of fibroblasts and hepatic stellate cells, has a good treatment effect on a bleomycin-induced mouse pulmonary fibrosis model, and is equivalent to the clinical medicament of nintedanib for treating pulmonary fibrosis. The series of compounds provided by the invention have better anti-tumor and anti-fibrosis activities, and provide a new choice for development and application of anti-tumor and anti-fibrosis drugs.
Participants received sarilumab-matching placebo as SC injection q2w up to 52 weeks along with the combination of prednisone and/or prednisone-matching placebo according to the protocol-defined schedule. Participants received prednisone tapering oral daily doses during the first 26 weeks and prednisone-matching placebo from Week 26 up to Week 52.